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Abstract: A biomarker is “a naturally occurring molecule, gene, or characteristic by 
which a particular pathological or physiological process, disease, etc. can be identified” 
and it could be used a measurable indicator for the presence or severity of disease state. 
YKL-40 is a secreted glycoprotein associated with extracellular matrix, a member of the 
mammalian chitinase-like proteins that is expressed in a several types of solid tumors. 
Although the implication of this biomarker in tissue remodeling processes or the role in 
cancer cell proliferation, invasiveness, angiogenesis, and remodeling of the extracellular 
matrix is going to be well recognized, the regulation and role in glioblastoma multiforme 
(GBM) progression remains unknown. Using the serum level of YKL-40 as a single 
screening test in cancer cannot be used, but in association with other tumoral biomarkers 
and imaging techniques can be a useful tool as a “prognosticator.” Moreover, elucidation 
of the YKL-40 functions could be an attractive target for antitumor therapy. 
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Introduction 
In the last 10 years great efforts were made 
to find new biological markers in human 
pathology, and special attention was done to 
discover new tumoral markers that could help 
in defining new treatment possibilities, and to 
offer a better way to perform a prognosis with 
a high accuracy. High grade glioma represent 
an important group of human brain tumors, 
and in this respect finding new characteristics 
in their biology could open new ways in what 
represent challenges in therapy for this highly 
malignant with rapid evolution, and a dismal 
prognosis. The majority of the primary tumors 
of the central nervous system are represented 
by gliomas, and they are classified according 
to WHO into four different classes with the 
grade IV or glioblastoma multiforme (GBM) 
exhibiting the highest level of malignancy in 
terms of invasion, proliferation, angiogenesis, 
and necrosis. GBM is one of the most common 
primary brain tumor, and the most fatal in 
terms of survival, meaning that the survival 
time is 10 to 14 months with the current 
standard of care, including surgical removal, 
radiotherapy, and chemotherapeutic agent 
temozolomide. The GBM cells aggressively 
infiltrates the surrounding brain tissue, and this 
is the cause of his very high recurrence rate.[1] 
The complex nature of these tumors lead to 
classified GBM in subtypes, just in an attempt 
to guide research to develop new targeted 
therapies, listed in the best prognostic order as 
Neural, Pro-neural, Classical, and 
Mesenchymal. The Neural and Pro-neural 
resembles normal brain cells, in contrast with 
Classical and Mesenchymal subtypes that are 
much less differentiated and have a much 
worse prognosis.[2] 
One of the most overexpressed proteins by 
GBM cells is YKL-40. Is a glycoprotein that 
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play a major role in the maturation of some 
cells of the immune system and it’s 
implications in inflammatory diseases and in 
some forms of solid tumors is growing. But, 
the exact mechanisms of YKL-40 in GBM 
remain unknown, and to validate it as a 
biomarker needs more work to be done. 
 
 
CHI3-L1/YKL-40 
In the last years a secreted glycoprotein 
associated with extracellular matrix, YKL-40, 
was identified to be the most highly up-
regulated protein, and even more the 
microarray analysis offer the information that 
YKL-40 could be one of the most 
overexpressed genes compare to normal brain 
tissue, but the role in progression of GBM 
remains elusive.[1] 
This glycoprotein in the light of the last 
years could represent a possible biomarker 
used in situation of patients with high grade 
gliomas (HGG), but according to the tumor 
marker utility grading system, a number of 
requirements must fulfilled before considering 
to have reached level of evidence I (LOE I) to 
be clinical implementation feasible. In the 
most situations, including YKL-40, the studies 
of biomarkers are at the level LOE III, defined 
as retrospective studies. The LOE II, an 
intermediate level, is defined as studies with 
prospectively collected specimens.[3] 
The 18 glycosyl hydrolase family of 
chitinases is widely expressed from 
prokaryotes to eukaryotes, including 
mammals, despite the absence of endogenous 
chitin. Acidic mammalian chitinase (AMCase) 
play a multiple roles including inhibiting 
chitin-induced innate inflammation; augments 
chitin-free, allergen-induces Th2 
inflammation; and mediates effector functions 
of IL-13. The YKL-40/chitinase-like proteins 
BRP-39 plays important roles in inhibiting 
oxidant-induced lung injury, augments 
adaptive Th2 immunity, regulates apoptosis, 
stimulates alternative macrophage activation, 
and contributes to fibrosis and wound 
healing.[4] 
YKL-40 was first discovered in human 
osteosarcoma cell line, MG-63, and is a 40 
kDa protein, and its first three aminoacids - 
tyrosine, lysine, and leucine - giving his name. 
Even YKL-40 can bind to chitin directly, but 
the glycosyl hydrolase activity to break down 
chitin is absent. 
The YKL-40 is expressed by activated 
neutrophils, macrophages, vascular smooth 
cells, and chondrocytes and play an important 
role in extracellular matrix remodeling, 
macrophage induced inflammation, and T-cell 
function. That’s why the YKL-40, implicated 
in maturation of some cells of the immune 
system, especially macrophages, may act as a 
prognostic marker for inflammatory diseases 
and cancer, but the role of YKL-40 in relation 
to tumors development and progression still 
remains unknown, and more work must be 
done to validate it as a tumoral marker. 
The location of gene encoding the YKL-40 
is on chromosome 1q32.1, and chitinases 
(including YKL-40) are endo--1,4-
Nacetylglucosamides are part of the innate 
immune response being involved in the host 
defense against organisms that contain chitin, 
which is found in the cell walls of many 
bacteria and fungi.[1] 
 
 
YKL-40 SERUM LEVEL IN PATIENTS 
WITH TUMORS 
The serum level of the YKL-40 is found 
elevated in patients with different types of 
solid tumors, including adenocarcinomas, 
small cell lung carcinoma, glioblastoma, and 
melanoma, with the highest level in patients 
with advanced cancer and the poorest 
prognosis, and in many cases could provides 
independent information of survival, but at this 
time he cannot be used as a single screening 
test for cancer.[3] 
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In vitro, YKL-40 is secreted by a number 
of cell lines, including the glioblastoma cell 
line U87 and the glioma cell lines U1242MG, 
U343MG and U1231MG. Microarray gene 
analyses in glioblastomas and astrocytomas 
showed that YKL-40 is overexpressed 
compared to normal tissue, and it’s expression 
increases with glioma grade, being higher in 
glioblastoma than in astrocytic or 
oligodendroglial tumors. This high expression 
of YKL-40 was associated with a poor 
response to radiotherapy and a short time to 
disease progression and death. For adult 
patients operated for HGG, plasma level of 
YKL-40 during follow-up was lower in cases 
with no radiographic evidence of recurrences 
compared to patients with signs of disease and 
was associated with short survival, but in 
pediatric HGG overexpression of YKL-49 is 
less frequent and is not correlated with 
survival.[5] 
The results show that YKL-40 plays a 
pivotal role in proliferation of glioma cells 
through activation of the MAPK and AKT 
pathways [6], and suppression by shRNA 
reduced glioma cell invasion, anchorage-
independent growth and increase cell death 
triggered by chemotherapy (e.g. cisplatin, 
etoposide and doxorubicin).[7] 
 
 
YKL-40 AND ANGIOGENESIS 
Tumor cell invasion and metastasis can be 
influenced by inhibition of angiogenesis, and 
blockading vascular endothelial growth factor 
receptor-2 (VEGFR-2) with monoclonal 
antibody DC101 inhibit GBM cell growth, but 
can increase tumor cell invasion using the 
preexistent vasculature. This increased 
invasion of the GBM cell can be inhibited by 
simultaneous blockade of epidermal growth 
factor receptor (EGFR).[8] 
Clinical trials in recurrent GBM testing an 
anti-VEGF antibody show minimal benefit in 
terms of survival. Moreover, a knockdown of 
the VEGF gene in the U87 GBM cell line will 
up-regulate YKL-40 levels, and remains to be 
determined the regulatory relationship 
between YKL-40 and VEGF, but both act as 
potent angiogenic factors in a synergistic 
effects on angiogenesis.[1] 
The YKL-40 is not regulated by VEGF, 
and a long-term blockade of VEGF will have 
an angiogenic compensative activity of GBM 
cells by inducing YKL-40. The phenomenon 
of promoting vascular development observed 
in tumor models treated chronically with a 
single anti-angiogenic drug is known as 
angiogenic rebound.[9][10] 
Studies demonstrated that YKL-40 could 
enhance angiogenesis, radioresistance, and 
progression of GBM cells, and in the end 
YKL-40 can drove GBM cells into 
mesenchymal phenotype, where the tumor 
cells act as mural-like cells.[2] 
The receptors for YKL-40 still remains 
unknown, but YKL-40 induces interactions 
between integrin 3 and sindecan-1 in 
endothelial cells, though sindecan-1 don’t 
mediate migration and invasion of GBM cells 
induced by YKL-40. Other studies indicated 
that extracellular matrix is important for 
migration and invasion of the glioma cells, and 
YKL-40 can bind the heparin binding domain 
of syndecan-1, a transmembrane heparin 
sulfate proteoglycan in endothelial cells. 
However, syndecan-4 is at high levels in all 
glioma cells, and his down-regulation will 
reduced YKL-40-induced U373 cells 
migration.[1] 
 
 
 
YKL-40 IN CLINICAL PRACTICE 
Recently, YKL-40 was introduced into 
clinical practice, but its application remains 
restricted.[11] The serum level of YKL-40 and 
MMP-9 can be monitored to help confirm the 
absence of active disease in GBM and YKL-
40 in anaplastic glioma patients.[12] 
In a study made for YKL-40 expression in 
36 patients with glial tumors and 33 age-
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matched healthy persons, expression of YKL-
40 was measured by gene analysis, 
immunohistochemistry and ELISA. In patients 
with HGG the YKL-40 serum levels was 
significantly increased compare to healthy 
subjects, and serum concentrations increased 
with tumor grade and correlated positively 
with transcript rate.[13] 
A prospective longitudinal study made a 
correlation between the serum levels of YKL-
40 and MRI findings in 197 patients with 
GBM. In patients with no radiographic 
evidence of disease the serum levels of YKL-
40 was significantly lower compared to 
patients with radiographic evidence of tumor. 
Furthermore, a smaller study was made in 60 
patients with GBM who underwent gross total 
resection or subtotal resection, and showed 
that in patients who had more extensive tumor 
resection the levels of YKL-40 dropped 
postoperatively. In a study of 105 patients, the 
most important prognostic factors in patients 
with primary GBM were the extent of 
resection, MGMT promoter methylation status 
and YKL-40 expression by 
immunohistochemistry.[14] Also, longitudinal 
increases in serum level of YKL-40 is 
associated with increased risk of death in 
patients with GBM or anaplastic gliomas.[15] 
Glial fibrillary acidic protein is the current 
standard immunohistochemical marker used to 
differentiate between different types of 
gliomas, but in one study YKL-40 staining 
offer a better distinction of GBM versus 
anaplastic oligodendroglioma, and a 
combination of those two staining’s offer even 
a greater diagnostic accuracy.[16] Despite 
identical histological features, the biology of 
HGG in children differs from that in 
adults.[17] 
 
 
DOES THERAPY INFLUENCE YKL-40 
SERUM LEVEL? 
In a study of 60 patients who underwent a 
standard treatment (surgery, radiotherapy and 
chemotherapy) and standard radiological 
monitoring (MRI at pre-defined stages) the 
YKL-40 serum level was evaluated. Patients 
were divided in two groups based on the extent 
of resection (total or subtotal) in accordance 
with MRI results after 48 hours following 
surgery. At multivariate analysis a significant 
hazards ratio of 1.97 was found, and a 
significant association with shorter outcome in 
patients whose postoperative YKL-40 
concentration increases higher than 100%; a 
negative prognostic index is still considered 
for a 50% increase. As a conclusion, 
biomarker YKL-40 could provide earlier and 
additional information and is a further aid in 
establishing the prognosis of GBM patients 
who undergone surgery.[18] 
In another study, poorer radiation response, 
shorter time to progression and shorter overall 
survival was associated with higher YKL-40 
expression in the subtotal resection group and 
it was validated in the gross-total resection 
group by association with higher YKL-40 
expression. The YKL-40 was an independent 
predictor of survival, after adjusting for patient 
age, performance status, and extent of 
resection.[19] 
A combination of preoperative profile 
IGFBP-2, GFAP, and YKL-40 plasma levels 
could serve as an additional tools for patients 
with inoperable brain lesions suggestive of 
GBM.[20] 
The most important factor who influence 
the OS of patients with GBM is the extent of 
removal, and is an independent prognostic 
factor that predicts OS better than MGMT 
status.[21] 
A mouse monoclonal anti-YKL-40 
antibody (mAY) bind specifically with 
recombinant YKL-40 and with YKL-40 
secreted from osteoblastoma cells MG-63 and 
brain tumor cells and thus inhibit tube 
formation of microvascular endothelial cells; 
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also abolish activation of the membrane 
receptor VEGF receptor 2 and intracellular 
signaling mitogen-activated protein kinase 
extracellular signal-regulated kinase (Erk) 1 
and Erk 2; enhance cell death response of U87 
line to γ-irradiation.[22] Thus the conjunction 
therapy with mAY and radiotherapy 
synergistically inhibit vascularization and 
progression in tumor.[23] 
YKL-40 can be used as predictor of 
survival in patients with HGG, and 
longitudinal studies with a larger patient 
population are needed to confirm these 
findings.[12] 
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Conclusion 
CAN WE USE YKL-40 AS A BIOMARKER 
IN GBM? 
YKL-40, this 40kDa glycoprotein 
belonging to the chitinase family but without 
chitin hydrolase activity is a new possible 
biomarker in GBM. It acts as an antiapoptoic 
protein, but the exact mechanism in GBM 
progression, invasiveness and angiogenesis 
remains elusive. 
According to Werner et al. there are six 
different clinical criteria to assess the value of 
tumor markers in clinical practice, such as 
biochemical characteristics, organ specificity, 
or clinical usefulness.[24] YKL-40 is neither 
organ- nor tumor-specific, and in the “tumor 
marker utility grading system” introduced by 
Hayes and colleagues is on the “utility scale +” 
and “utility scale +/-”, indicate that serum 
level of YKL-40 may have a role in screening 
and monitoring of patients with cancer.[25] 
The importance of YKL-40 in screening and 
monitoring of the patients with GBM needs to 
be proved by appropriate prospective study in 
which is assessed the benefit of using serum 
levels of YKL-40 in clinical decision-making 
process. 
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